Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial.
10.7499/j.issn.1008-8830.2109106
- Author:
Meng-Meng LIU
1
;
Ling JI
1
;
Meng-Yuan DONG
1
;
Xiao-Fan ZHU
1
;
Hui-Juan WANG
1
Author Information
1. Department of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
- Publication Type:Randomized Controlled Trial
- Keywords:
Bronchopulmonary dysplasia;
Budesonide;
Preterm infant;
Pulmonary surfactant
- MeSH:
Bronchopulmonary Dysplasia/prevention & control*;
Budesonide;
Humans;
Infant;
Infant, Newborn;
Infant, Premature;
Prospective Studies;
Pulmonary Surfactants/therapeutic use*;
Respiration, Artificial;
Respiratory Distress Syndrome, Newborn/therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(1):78-84
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To study the efficacy and safety of early intratracheal administration of budesonide combined with pulmonary surfactant (PS) in preventing bronchopulmonary dysplasia (BPD).
METHODS:A prospective randomized controlled trial was designed. A total of 122 infants with a high risk of BPD who were admitted to the neonatal intensive care unit of the Third Affiliated Hospital of Zhengzhou University from January to July 2021 were enrolled. The infants were randomly divided into a conventional treatment group with 62 infants (treated with PS alone at an initial dose of 200 mg/kg, followed by a dose of 100 mg/kg according to the condition of the infant) and an observation group with 60 infants (treated with PS at the same dose as the conventional treatment group, with the addition of budesonide 0.25 mg/kg for intratracheal instillation at each time of PS application). The two groups were compared in terms of the times of PS use, ventilator parameters at different time points, oxygen inhalation, incidence rate and severity of BPD, incidence rate of complications, and tidal breathing pulmonary function at the corrected gestational age of 40 weeks.
RESULTS:Compared with the conventional treatment group, the observation group had a significantly lower proportion of infants using PS for two or three times (P<0.05). Compared with the conventional treatment group, the observation group had a significantly lower fraction of inspired oxygen at 24 and 48 hours and 3, 7, and 21 days after administration, significantly shorter durations of invasive ventilation, noninvasive ventilation, ventilator application, and oxygen therapy, a significantly lower incidence rate of BPD, and a significantly lower severity of BPD (P<0.05). There was no significant difference in the incidence rate of glucocorticoid-related complications between the two groups (P>0.05).
CONCLUSIONS:Compared with PS use alone in preterm infants with a high risk of BPD, budesonide combined with PS can reduce repeated use of PS, lower ventilator parameters, shorten the duration of respiratory support, and reduce the incidence rate and severity of BPD, without increasing the incidence rate of glucocorticoid-related complications.
